蒲地蓝消炎两种剂型抗炎活性比较及机制研究
该研究比较蒲地蓝消炎口服液与配方颗粒的抗炎药效及机制,采用小鼠耳肿胀、腹腔毛细血管通透性、大鼠足肿胀模型及斑马鱼炎症模型。结果显示两者抗炎效果无显著差异,配方颗粒可能通过调控糖酵解和TLR4/NF-κB/NLRP3通路发挥抗炎作用。
要点
- 蒲地蓝消炎口服液与配方颗粒在多种炎症模型中抗炎效果无显著差异。
- 配方颗粒可能通过抑制糖酵解和TLR4/NF-κB/NLRP3通路减轻炎症。
- 配方颗粒或可作为口服液的临床替代剂型。
核心结论
- 蒲地蓝消炎配方颗粒抗炎效果与口服液相当或更优,可能通过调控糖酵解和TLR4/NF-κB/NLRP3通路发挥作用。
研究设计与样本
- 研究采用HPLC定性分析配方颗粒成分,并利用小鼠耳肿胀、腹腔毛细血管通透性、大鼠足肿胀及斑马鱼LPS炎症模型比较两种剂型抗炎效果。
主要发现
- 两种剂型均显著减轻耳肿胀、腹腔毛细血管通透性和足肿胀,且效果无显著差异。
- 在斑马鱼模型中,两者均抑制中性粒细胞浸润和巨噬细胞聚集,降低炎症因子释放,延长存活率。
- 在急性肺损伤模型中,两者均减轻肺部炎症,下调糖酵解相关蛋白并抑制TLR4/NF-κB/NLRP3信号通路。
临床怎么用
- 蒲地蓝消炎配方颗粒可作为口服液的替代剂型用于炎症相关疾病。
局限性
- 研究未报告两种剂型的临床疗效直接比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Pudilan xiaoyan oral liquid (PDL-L), a antipyretic and toxin-eliminating agent used in China for inflammatory conditions including sore throat and tonsillitis, is a standardized Chinese patent medicine. Pudilan formula granules (PDL-G), which share the same composition as PDL-L, are another dosage form of this medication. However, the difference in anti-inflammatory efficacy between PDL-L and PDL-G remains unevaluated, and their potential mechanisms require further exploration. AIM OF THE STUDY: The present work systematically investigates comparative pharmacodynamic differences between PDL-L and PDL-G and their underlying mechanisms. MATERIALS AND METHODS: Qualitative analysis of key bioactive constituents in PDL-G was conducted using high performance liquid chromatography (HPLC) to ensure pharmaceutical quality standards. The anti-inflammatory effects of PDL-L and PDL-G were compared using three established models: the mouse auricular swelling model, the abdominal capillary permeability model, and the rat paw edema model. Additionally, to establish an inflammatory phenotype, zebrafish embryos at 3-day-post-fertilization received microinjection of 2-nL LPS solution (3 mg/mL) into the yolk sac region for inflammatory challenge. Comparative evaluation of anti-inflammatory efficacy between PDL-L and PDL-G were compared by larval survival analysis and observation of neutrophils and macrophages migration. Quantitative real-time PCR (qRT-PCR) was employed to measure transcriptional levels of pro-inflammatory cytokines and TLR4/NF-κB/NLRP3 pathway components in LPS-challenged zebrafish. The inhibitory effects of PDL-L and PDL-G on LPS- and Poly (I:C)-induced acute lung injury (ALI) were evaluated in mice through enzyme-linked immunosorbent assay (ELISA) and qRT-PCR. Pathological damage was evaluated via hematoxylin-eosin (H&E) staining. A concurrent evaluation was performed on glycolytic-related protein expression and TLR4/NF-κB/NLRP3 signaling activation in ALI mice. RESULTS: Qualitative profiling of eight principal constituents in PDL-G and PDL-L was achieved through simultaneous chromatographic detection. Both PDL-L and PDL-G exhibited remarkable anti-inflammatory effects in several types of inflammation models. Both two formulations reduced ear swelling, abdominal capillary permeability, and paw edema with no significant difference in efficacy. In zebrafish inflammation model, PDL-L and PDL-G both significantly suppressed neutrophils infiltration and macrophages accumulation in LPS-challenged zebrafish larvae, reduced the release of LPS-stimulated inflammatory factors, and prolonged larval survival through the TLR4/NF-κB pathway inhibition coupled with NLRP3 inflammasome suppression. In murine models of LPS/Poly (I:C)-induced ALI, both PDL-L and PDL-G effectively mitigated pulmonary inflammation through suppression of pro-inflammatory mediator secretion in bronchoalveolar lavage fluid and lung tissues. Furthermore, these treatments downregulated the expression of glycolysis-associated proteins and suppressed the signaling activity of the TLR4/NF-κB/NLRP3 inflammatory cascade. CONCLUSION: This investigation first provides experimental evidence that PDL-G demonstrates comparable or even superior efficacy to PDL-L in anti-inflammatory effects. Our results also show that PDL-G exerts anti-inflammatory activity through regulation of glycolysis and the TLR4/NF-κB/NLRP3 pathway. These findings substantiate PDL-G's clinical substitution potential for PDL-L, providing a molecular rationale for its therapeutic translation in inflammatory disorders.
引用
- Xu N, Lu X, Yu J, et al. Modulation of glycolytic metabolic reprogramming and the TLR4/NF-κB/NLRP3 Pathway: comparative analysis of anti-inflammatory activity between two dosage forms of Pudilan xiaoyan. J Ethnopharmacol. 2025. PMID: 40571230. doi:10.1016/j.jep.2025.120204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。